MAPK3 and melanoma: Treatment of melanoma cells with inhibitor of ERK1/2 kinase—U126 and B-RAF-GDC-0879, resulted in the most profound reduction in expression of cyclin D1 and CDK4 kinase but only slightly affected the level of cyclin D3 and CDK6 kinase.